Nanomedicine Journal Receives Rapid Acceptance by ISI® Science Citation Index

Future Medicine Ltd has announced that its journal Nanomedicine has been selected for coverage in ISI® services after the publication of only five issues.

“We at Nanomedicine are delighted that the journal has been accepted for coverage by ISI after only one year. This speaks not only to the importance of the field, but also to the high quality of the articles and features published to date in Nanomedicine. We also recognize that the outstanding scientists on our editorial advisory board played a large role in the rapid development of Nanomedicine, and we look forward to continuing fruitful interactions with the board and with all the authors who choose to publish their excellent work in Nanomedicine.”, says Professor Charles R Martin, Director of the Center for Research at the Bio/Nano Interface and Colonel Allen R and Margaret G Crow Professor of Chemistry, University of Florida (FL, USA), and Senior Editor of the journal.

Kostas Kostarelos, Centre for Drug Delivery Research, University of London (UK) and also Senior Editor of the journal commented; “Recognition by the Institute of Scientific Information is considered by all of us in the journal as an indication that nanomedicine is entering the mainstream of scientific advance and that the journal Nanomedicine is at the forefront of this field. We are determined to grow stronger as a journal and contribute to medical practice as a whole.”

Topics covered in the first year of publication by Nanomedicine include basic research and theoretical applications of nanomedical technology, potential medical applications and therapeutic applications of nanotechnology advances, nanomedical tools in gene therapy, drug delivery and commercialization, funding, economics and ethics of nanomedical technology.

Morag Robertson, Editor at Future Medicine said; “We are delighted that Nanomedicine has been accepted by Thomson ISI at this early stage of the journal’s development. The field of nanotechnology and its medical applications has become one of the hottest areas in science today and the launch of Nanomedicine has been greeted with huge interest."

Robertson further said, "we would like to thank the journal’s Senior Editors, Professor Charles Martin and Dr Kostas Kostarelos, for their encouragement as well as our outstanding Editorial Board for their input and guidance thus far. We anticipate further success with Nanomedicine as we move forward.”

The Senior Editors and Future Medicine Ltd aim to make Nanomedicine the main forum in which the challenges and advances in nanotechnology research related to medicine are addressed. In upcoming years, the field promises much – Nanomedicine will be there to highlight the main advances and therapeutic possibilities for clinicians and researchers alike and will provide an avenue for debate of controversial issues.